Gemcitabine resistance in non‐small cell lung cancer is mediated through activation of the PI3K/AKT/NF‐κB pathway and suppression of ERK signaling by reactive oxygen species

Abstract

AbstractLung cancer is one of the most common cancers in the world. Chemotherapy is a standard clinical treatment. However, tumor cells often develop multidrug resistance after chemotherapy, an inevitable bottleneck in cancer treatment. Therefore, this study used gemcitabine‐resistant (GEM‐R) CL1‐0 lung cancer cells. First, we used flow cytometry and western blot analysis to examine differences in performance between resistant and parental cells. The results showed that compared with parental cells, GEM‐R CL1‐0 cells significantly enhanced the activation of the AKT pathway, which promoted survival and growth, and decreased the activation of the reactive oxygen species‐extracellular signal‐regulated kinase (ROS)‐ERK pathway. Next, the AKT and ERK pathways' role in tumor growth was further explored in vivo using a xenograft model. The results showed that enhancing AKT and inhibiting ERK activation reduced GEM‐induced inhibition of tumor growth. Finally, combining the above results, we found that GEM‐R CL1‐0 cells showed reduced sensitivity to GEM by activating the phosphatidylinositol 3‐kinase/AKT/NF‐kB pathway and inhibiting the ROS‐ERK pathway leading to resistance against GEM. Therefore, the AKT and ERK pathways are potential targets for improving the sensitivity of cancer cells to anticancer drugs.